현재 검색어 자동 추천 기능을 사용하고 있습니다. 검색어 입력시 자동으로 관련어를 추천합니다.자동 추천 기능을 사용해 보세요. 검색어 입력시 자동으로 관련어를 추천합니다.
홈대한소화기기능성질환·운동학회>Gut and Liver>Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial
Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial
Yoon Jin Choi , Yong Chan Lee , Jung Mogg Kim , Jin Il Kim , Jeong Seop Moon , Yun Jeong Lim , Gwang Ho Baik , Byoung Kwan Son , Hang Lak Lee , Kyoung Oh Kim , Nayoung Kim , Kwang Hyun Ko , Hye-kyung Jung , Ki-nam Shim , Hoon Jai Chun , Byung-wook Kim , Hyuk Lee , Jie-hyun Kim , Hyunsoo Chung , Sang Gyun Kim , Jae Young Jang
: Gut and Liver 16권4호
: 2022년 07월
MATERIALS AND METHODS
CONFLICTS OF INTEREST
Background/Aims: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.
Methods: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.
Results: In total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.
Conclusions: TPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier NCT03317223). (Gut Liver 2022;16:535-546)
: 의약학분야 > 내과학
한국학술정보㈜의 모든 학술 자료는 각 학회 및 기관과 저작권 계약을 통해 제공하고 있습니다.
이에 본 자료를 상업적 이용, 무단 배포 등 불법적으로 이용할 시에는 저작권법 및 관계법령에 따른 책임을 질 수 있습니다.